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OBJECTIVES The purpose of this study was to determine whether endurance exercise training could buffer
neuroendocrine activity in chronic heart failure patients.
BACKGROUND Neuroendocrine activation is associated with poor long-term prognosis in heart failure. There
is growing consensus that exercise may be beneficial by altering the clinical course of heart
failure, but the mechanisms responsible for exercise-induced benefits are unclear.
METHODS Nineteen heart failure patients (ischemic disease; New York Heart Association [NYHA] class
II or III) were randomly assigned to either a training group or to a control group. Exercise
training consisted of supervised walking three times a week for 16 weeks at 40% to 70% of
peak oxygen uptake. Medications were unchanged. Neurohormones were measured at study
entry and after 16 weeks.
RESULTS The training group (n 5 10; age 5 61 6 6 years; EF 5 30 6 6%) and control group (n 5
9; age 5 62 6 7 years; EF 5 29 6 7%) did not differ in clinical findings at study entry. Resting
levels of angiotensin II, aldosterone, vasopressin and atrial natriuretic peptide in the training and
control groups did not differ at study entry (5.6 6 1.3 pg/ml; 158 6 38 pg/ml; 6.1 6 2.0 pg/ml;
37 6 8 pg/ml training group vs. 4.8 6 1.2; 146 6 23; 4.9 6 1.1; 35 6 10 control group). Peak
exercise levels of angiotensin II, aldosterone, vasopressin and atrial natriuretic peptide in the
exercise and control groups did not differ at study entry. After 16 weeks, rest and peak exercise
hormone levels were unchanged in control patients. Peak exercise neurohormone levels were
unchanged in the training group, but resting levels were significantly (p , 0.001) reduced
(angiotensin 226%; aldosterone 232%; vasopressin 230%; atrial natriuretic peptide 227%).
CONCLUSIONS Our data indicate that 16 weeks of endurance exercise training modified resting neuroendo-
crine hyperactivity in heart failure patients. Reduction in circulating neurohormones may have
a beneficial impact on long-term prognosis. (J Am Coll Cardiol 1999;34:1170–5) © 1999 by
the American College of Cardiology
Neurohormonal mechanisms play a central role in the
progression of chronic heart failure (CHF) (1–6). Activa-
tion of the sympathetic nervous system and activation of the
renin-angiotensin-aldosterone system (RAAS) have adverse
hemodynamic consequences in heart failure in part because
they enhance vasoconstriction and promote fluid retention.
Furthermore, prolonged neurohormonal activation exerts a
direct deleterious effect on the heart that is independent of
the hemodynamic actions of these systems (7–10). High
concentrations of angiotensin II (ANG II) induce necrosis
of cardiac myocytes (7,8), adversely influence matrix struc-
ture of myocardium (10), increase sympathetic neural drive
(9) and impair baroreceptor restraint on sympathetic drive
(9). Compelling evidence has been provided that pharma-
cologic suppression of neurohormonal activation, rather
than direct stimulation of the failing myocardium, improves
symptoms and survival in CHF (6,9,11–13). These obser-
vations support the need for more therapeutic strategies to
modulate neurohormonal activation in CHF.
There is growing clinical consensus that exercise training
may beneficially alter the clinical course of CHF. However,
the specific mechanisms responsible for exercise-induced
benefits are unclear. Previous studies in subjects with normal
left ventricular function have demonstrated that regular
endurance exercise reduces central sympathetic tone (14–
16), increases parasympathetic activity (17), decreases
plasma renin activity (18) and improves baroreflex sensitivity
(19–21). To date, however, no randomized controlled study
has investigated the influence of longer-term exercise train-
ing on neurohormonal activation in CHF patients.
The purpose of the present study was to determine the
effect of intermediate-term endurance exercise training on
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resting and exercise-induced neurohormonal activation in
CHF patients. We hypothesized that exercise could exert a
modulating effect upon plasma levels of arginine vasopressin
(AVP), alpha-atrial natriuretic peptide (ANP), aldosterone
(ALDO) and ANG II. Accordingly, we measured plasma
neurohormonal levels at rest and immediately after maximal
treadmill exercise in CHF patients before and after either a
16-week exercise training program or control period.
METHODS
Subjects. Nineteen clinically stable coronary artery disease
patients with chronic (.4 months) New York Heart Asso-
ciation class II or III symptoms of heart failure were
recruited to participate in the study (Table 1). Coronary
artery disease was documented by confirmed myocardial
infarction (World Health Organization criteria) or coronary
angiography (.50% diameter stenosis in a major coronary
artery). All had systolic left ventricular (LV) dysfunction
documented by an ejection fraction ,40%. Pharmacologic
therapy with digoxin, angiotensin-converting enzyme
(ACE) inhibitors, diuretics, and beta-adrenergic blocking
agents had been optimized and maintained for at least one
month (Table 1). Pharmacologic therapy was not altered for
any subjects after entry into the study.
Contraindications for participation in the study included
recent new myocardial infarction (,5 weeks), unstable
angina, uncontrolled hypertension or diabetes, significant
chronic lung disease, renal failure, cardiac pacemaker or
internal defibrillator or musculoskeletal disorder that hin-
dered the ability to exercise. The study protocol was
approved by the Institutional Review Board for the protec-
tion of human research subjects at the University of Florida,
and all subjects provided written informed consent to
participate in the study.
Study design. The study design included a screening and
recruitment period, and a randomly assigned treatment
period. The treatment period had two parallel arms consist-
ing of a control and exercise training limb with each lasting
16 weeks.
Exercise testing. Before and after application of exercise
training, all subjects completed a modified Naughton tread-
mill protocol for determination of symptom-limited peak
oxygen consumption (VO2peak). Treadmill speed remained
constant at 2 mph and elevation was increased by 2% grade
every 2 min until termination of the test. Expired gasses
were collected and analyzed using a metabolic cart (Medical
Graphics, St. Paul, Minnesota). Minute ventilatory volume
and fractional concentrations of oxygen and carbon dioxide
were determined from breath-by-breath expired air samples
and used to calculate VO2peak. Heart rate, 12-lead electro-
cardiogram (ECG), and blood pressure were monitored and
recorded throughout the test. Subjective assessment of
angina and dyspnea was attained using the 4-point scales
recommended by the American College of Sports Medicine
(22).
Blood sample collection. Venous blood samples for deter-
mination of plasma neurohormone concentrations were
collected before and immediately after treadmill tests. A
21-gauge catheter was inserted into a forearm vein 30 min
before the treadmill test. At 2 min before the start of the
treadmill test, a 20-ml sample of blood was collected, and a
second 20-ml sample was drawn immediately on comple-
tion of the treadmill test. All blood was collected with
subjects in the standing posture.
Blood samples were withdrawn into a plastic syringe
containing no additives and were immediately separated
into individual aliquots. Blood for AVP, ANG II, ALDO,
and ANP assays was added to chilled vacutainers containing
EDTA. Plasma was separated by centrifugation at 3,000 g
at 4°C for 20 min and the samples were frozen at 280°C
until the completion of the study so that all samples for each
subject could be run in the same assay.
Neurohormone assays. Plasma AVP was measured by
radioimmunoassay as previously described (23). Plasma
ANG II and ALDO levels were determined by radioim-
munoassay as previously described by Braith et al. (24).
Also, ANP was extracted from plasma using a modification
of a technique described by Braith et al. (25). Plasma (1 ml)
was deproteinized by adding 750 ml 0.1 mol/liter acetic acid
and 1.25 ml methanol. Samples were placed on a rocking
shaker for 10 min followed by centrifugation for 20 min at
6,000 g at 4°C. The supernatant was dried by vacuum
Abbreviations and Acronyms
ALDO 5 aldosterone
ANG II 5 angiotensin II
ANP 5 alpha-atrial natriuretic peptide
AVP 5 arginine vasopressin
CHF 5 chronic heart failure
RAAS 5 renin-angiotensin-aldosterone system
VO2peak 5 symptom-limited peak oxygen consumption
Table 1. Descriptive Characteristics of Heart Failure Patients in
the Control and Exercise Training Groups Before 16 Weeks of
Endurance Exercise or Control Period
Training Group
(n 5 10)
Control Group
(n 5 9)
Age (yr) 61 6 6 62 6 7
NYHA (Class) 2.50 6 0.52 2.52 6 0.66
EF (%) 30.04 6 6.59 29.56 6 6.58
VO2peak (ml/kg/min) 13.00 6 4.23 12.89 6 3.56
Digitalis glycosides 8 8
ACE-inhibitors 7 6
Diuretics 8 8
Beta-blockers 2 2
Values are mean 6 SD.
NYHA 5 New York Heart Association classification for heart failure; EF 5 left
ventricular ejection fraction; VO2peak 5 peak exercise oxygen consumption.
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centrifugation. Radioimmunoassay was performed with a
kit from Peninsula Laboratories (Belmont, California) using
ANP antiserum that has 0% cross-reactivity with human
brain natriuretic peptide and C-type natriuretic peptide.
Group assignments and exercise training. After conclu-
sion of the screening procedures, the subjects were rank-
ordered by VO2peak and randomly stratified to either an
exercise group (n 5 10) or a control group that would not
participate in regular exercise training (n 5 9). The control
group reported to the laboratory each week during the
16-week study and saw the same physician and health care
team, and had the same monitoring of compliance, safety
and general physical condition as did the exercise training
group. This was part of a program of “usual care” for heart
failure patients in the Cardiovascular Medical Division at
the University of Florida.
Subjects randomized to the exercise group participated in
supervised treadmill walking. The initial exercise intensity
was 40% to 50% of VO2peak for a duration of 10 to 20 min,
as tolerated. Exercise intensity for all subjects was pro-
gressed to 70% to 80% of VO2peak for a duration of 30 to
45 min by approximately the 10th week of the study. All
exercise training sessions were monitored according to
established guidelines.
Statistical analysis. Descriptive characteristics of the sub-
jects were compared between groups using analysis of
variance (ANOVA). The VO2peak values and neurohor-
mone concentrations at rest and peak exercise, at entry and
at 16 weeks, were compared between groups using analysis
of covariance (ANCOVA). When a significant group-by-
time interaction was observed, between-group comparisons
were done using ANCOVA with contrast analysis for
obtaining appropriate post hoc custom hypothesis tests. All
statistical analyses were performed using the SAS statistical
program (SAS Institute, Cary, North Carolina). An alpha
level of p # 0.05 was chosen to represent statistical
significance.
RESULTS
At study entry, VO2peak did not differ between the two
groups (Table 1). The VO2peak did not change in the
control group after 16 weeks (12.8 6 3.5 vs. 12.0 6 3.3
ml/kg/min) but significantly increased (25%) in the exercise
training group (13.00 6 4.23 vs. 16.3 6 3.7 ml/kg/min).
At study entry, plasma concentrations of ANG II,
ALDO, AVP and ANP at standing rest did not differ (p $
0.05) between the two groups (Table 2). At termination of
the symptom-limited graded exercise test, all neurohor-
mones were significantly elevated above resting levels in
both groups, and the magnitude of increase was not signif-
icantly different between groups (p $ 0.05).
After 16 weeks the training group had significantly lower
resting plasma concentrations of ANG II, ALDO, AVP,
and ANP (Table 1). Resting values for all four of the
measured neurohormones were diminished by 20% to 30%
in the exercise group (Fig. 1). No significant changes in
resting neurohormone concentrations were observed in the
control group. In contrast, both the absolute and relative
increases in neurohormones at peak treadmill exercise were
similar (p $ 0.05) to values observed before training in both
groups.
DISCUSSION
To our knowledge, this is the first randomized controlled
trial of intermediate-term exercise training in CHF patients
that examined resting and exercise plasma levels of ANG II,
ALDO, AVP, and ANP. Our results indicate that, com-
pared with the untrained control group, the exercise trained
group had significant reductions (25% to 30%) in resting
levels of each neurohormone measured. In contrast, we did
not observe a training-induced reduction in levels of plasma
neurohormones at peak exercise. These data support the
hypothesis that exercise training buffers resting neuroendo-
Table 2. Plasma Neurohormone Concentrations for Both
Groups at Rest and Peak Treadmill Exercise Both Before and
After 16 Weeks of Exercise Training or Control Period
Variable
Control
Group
Exercise
Group
Rest Angiotensin II (pg/ml)†
Initial 4.8 6 1.2 5.6 6 1.3
4 Months 5.0 6 1.2 4.1 6 0.9*
Rest Aldosterone (pg/ml)†
Initial 146 6 23 158 6 38
4 Months 151 6 29 108 6 31*
Rest Vasopressin (pg/ml)†
Initial 4.9 6 1.1 6.1 6 2.0
4 Months 5.1 6 1.3 4.2 6 0.8*
Rest Atrial Natriuretic Peptide
(pg/ml)†
Initial 35 6 10 37 6 8
4 Months 37 6 11 27 6 6*
Peak Exercise Angiotensin II
(pg/ml)
Initial 16.4 6 2.2 17.9 6 1.6
4 Months 17.3 6 1.9 20.5 6 1.6
Peak Exercise Aldosterone
(pg/ml)
Initial 202 6 43 203 6 51
4 Months 209 6 39 199 6 47
Peak Exercise Vasopressin
(pg/ml)
Initial 20.0 6 3.1 17.9 6 4.5
4 Months 21.4 6 2.8 19.2 6 4.3
Peak Exercise Atrial Natriuretic
Peptide (pg/ml)
Initial 68 6 13 70 6 7
4 Months 76 6 15 67 6 8
*p # 0.05 after four months of training vs. initial value. †Measurement taken before
symptom-limited graded exercise test with subject standing.
Values are mean 6 SD.
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crine hyperactivity associated with CHF, but the neurohor-
monal activation in response to strenuous exercise stress
appears to be unaltered.
Neurohormone concentrations in health and disease.
The neurohormone assays used in the present study have
been used reliably in our laboratory for numerous experi-
ments with human subjects (24–26). Thus, intralaboratory
comparisons are possible that are not limited by the con-
founding problems associated with interlaboratory compar-
isons of biochemical data. In an attempt to interpret the
physiologic significance of the relative reductions in plasma
neurohormone levels in our trained CHF patients, we
compared results from the present study with neurohor-
mone levels in two reference groups: 1) age-matched
healthy subjects, and 2) age-matched orthotopic heart
transplant recipients recently studied in our laboratory (Figs.
2 and 3). The 16-week exercise training period used in our
CHF patients was associated with reductions in concentra-
tions of ANG II, ALDO and AVP to levels that are
comparable (p $ 0.05) with those observed in age-matched
sedentary reference subjects (no medications) and stable
heart transplant recipients (“standard transplant care”) (Figs.
2 and 3). Plasma ANP in trained CHF patients was also
reduced to levels observed in age-matched healthy subjects
(p $ 0.05) (Fig. 3).
Mechanism of neuroendocrine activation in CHF. Two
principal mechanisms are recognized in neurohormonal
activation in CHF patients, and both may be modulated by
endurance exercise training. One contends that neuroendo-
crine hyperactivity in CHF is triggered by baroreflex dys-
function in association with a prolonged exposure to low
cardiac output and reduced blood pressure. Sinoaortic and
cardiac baroreceptors normally exert a tonic inhibitory
influence on resting sympathetic activity, the kidney RAAS,
and AVP release (27). In CHF patients, tonic inhibitory
baroreflexes are depressed and contribute to sympathetic
excitation and elevated circulating neurohormone levels
(27–33).
An alternative but physiologically related mechanism for
neuroendocrine hyperactivity in CHF is associated with the
excitatory effects of circulating ANG II. Plasma ANG II
levels initially become elevated owing to renal underperfu-
sion, the primary stimulus for ANG II production by the
renal RAAS. Elevated ANG II exerts excitatory effects at
the level of the brain (34), ganglionic transmission (35) and
at adrenergic nerve terminals (36,37).
Exercise and baroreflex sensitivity. The present study was
not designed to investigate the possible mechanisms respon-
sible for neuroendocrine modulation in heart failure, but
several studies have suggested that strenuous endurance
exercise may improve baroreflex sensitivity. Convertino et
al. (19,20) have repeatedly observed that a single bout of
intense dynamic exercise increased the sensitivity of
baroreceptor-cardiac reflexes (i.e., heart rate regulation) and
baroreceptor-vascular reflexes (i.e., peripheral vascular resis-
tance regulation), independent of blood volume changes.
Pagani et al. (21) used a crossover design to investigate the
effects of exercise training (6 months of jogging) and not
training (4 months without jogging) on baroreceptor sensi-
tivity in 11 subjects with mild hypertension. The authors
Figure 1. Relative changes in angiotensin II (ANG II), aldoste-
rone (ALDO), arginine vasopressin (AVP), and atrial natriuretic
peptide (ANP) after four months of endurance exercise training or
control period. Data are mean 6 SEM. *p # 0.05 After training
versus before training.
Figure 2. Angiotensin II (top panel) and aldosterone (bottom
panel) concentrations drawn at rest in the standing posture for
age-matched healthy control subjects; heart transplant recipients;
heart failure patients before four months’ exercise training; and
heart failure patients after four months’ exercise training. Data are
mean 6 SEM. *p # 0.05 heart failure before training versus the
other three groups. †p # 0.05 versus heart failure after training and
normal control group.
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used IV phenylephrine to study the effects of training on the
heart rate–blood pressure relationship and reported a net
improvement in the tonic inhibitory activity of the major
constituents of the sympathetic-vagal balance. The mecha-
nism responsible for exercise-induced improvements in
baroreflex sensitivity is not understood. Investigators have
studied all components of the reflex arc, but specific mech-
anisms have not been identified because of the complexity of
the neural circuitry.
Baroreflex sensitivity and exercise capacity and survival
rate are also improved in CHF patients by administration of
ACE inhibitors (9,11,12,37,38). In aggregate, the
angiotensin-converting enzyme (ACE) inhibitor data sug-
gest that ANG II plays an important role in the central
integration of baroreflex information. Grassi et al. (9)
recently provided the first direct evidence, via muscle mi-
croneurography, that chronic ACE inhibitor treatment in
CHF patients caused both a reduction in central sympa-
thetic nerve traffic and an improved baroreceptor restraint
on sympathetic traffic. Thus, a reduction in circulating
ANG II achieved through exercise training may act favor-
ably on baroreflex control of sympathetic activity (9,39).
Cardiac output and renal perfusion. The exercise-
induced reduction of plasma neurohormones observed in
the present study could possibly be taken as a marker of
improved cardiac pump function. Certainly increased car-
diac output would augment renal perfusion and thereby
diminish the primary stimulus for activation of the kidney
RAA system. Although we did not measure cardiac output
in the present study, results from previous long-term train-
ing studies in CHF patients do not reveal evidence of
increased cardiac output. Sullivan et al. (40) reported a 23%
increase in VO2peak in patients with CHF (left ventricular
ejection fraction [LVEF] 24 6 10%) after four months of
exercise training, but there were no changes in rest or
exercise stroke volume, cardiac output or LVEF. Most
exercise training studies in CHF patients reporting im-
provements in VO2peak observe no changes in rest or
exercise measurements of left ventricular performance or
central hemodynamics. Rather, the beneficial elements of
the training response are attributed to peripheral adapta-
tions (41,42).
Study limitations. This study was limited by small sample
size, relatively brief duration of exercise training and absence
of outcome data. In addition, the study would be strength-
ened by inclusion of either direct (intraneural recordings) or
indirect (plasma norepinephrine or epinephrine data) in-
dexes of efferent sympathetic nerve traffic at study entry and
after 16 weeks. Finally, the CHF patients in the present
study were carefully selected, and they received very expert
heart failure and exercise training care that may not be
generalized.
Conclusions. It is generally believed that the neurohor-
monal activation in heart failure has an adverse prognostic
significance and that reduction in circulating neurohor-
monal levels by treatment represents a favorable therapeutic
effect. Thus, demonstration that endurance exercise training
is accompanied by a marked reduction (;25% to 30%) in
resting levels of plasma ANG II, ALDO, AVP, and ANP
has clinical implications. Currently, this demonstration has
only been provided in one small cohort of CHF patients
who trained for a period of 16 weeks.
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